Clinical Trials Browser

Phase 2 × Colorectal Neoplasms × dalotuzumab × Clear all

NCT00614393 2018-08-08

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Phase 2 Completed

558 enrolled 17 charts

Gastrointestinal

Colorectal Neoplasms

NCT01175291 2011-12-05

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Colorectal Neoplasms